Is Entrectinib covered by medical insurance?

Entrectinib (Entrectinib) is a multi-target tyrosine kinase inhibitor (TKI) drug used to treat malignant tumors carrying specific gene mutations. It mainly inhibits the growth and spread of tumors by inhibiting specific abnormal signaling pathways in tumor cells.

Entrectinib has been launched in China, but due to its short time on the market, it has not yet been included in the medical insurance catalog. Since it has just been launched, it is difficult to purchase domestically and the price is very high. For specific prices, please consult the hospital pharmacy at that time. There are original drugs and generic drugs abroad. The original drugs abroad are mainly European versions of original drugs. The price is about 45,000 yuan. The price is relatively high and may be unaffordable for ordinary families. Generic drugs are mainly Lao generic drugs, with prices ranging from 4,000 to 8,000yuan, which are much cheaper than original drugs, and the ingredients of original drugs and generic drugs are basically the same.

Enrectinib is mainly suitable for the following diseases:

1.Neuroblastoma (Neuroblastoma): A common childhood tumor, entrectinib can be used to treat neuroblastoma carrying NTRK gene fusion.

2.ROS1gene fusion-positive non-small cell lung cancer (NSCLC): Non-small cell lung cancer is a common type of lung cancer. Entrectinib can be used to treat NSCLC carrying the ROS1gene fusion.

3.ALKgene fusion-positive non-small cell lung cancer (NSCLC): It is also a non-small cell lung cancer. Entrectinib can also be used to treat NSCLC carrying ALKgene fusion.